Developer docs
API playgroundTry for free, no card

Search company profiles

Mindstate Design Labs

Full company profile

uuid0000d3e

Namestring
Mindstate Design Labs
Legal namestring
Mindstate Design Labs Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Mindstate Design Labs is a clinical-stage AI neuroengineering platform and drug development company founded in 2021 and headquartered in South San Francisco. The company's core technology, the Osmanthus platform, applies multi-agent large language models, custom embedding models, Bayesian neural networks, and biomedical knowledge graph analysis to a proprietary dataset of more than 60,000 human reports of psychoactive drug effects, synthesizing subjective phenomenology with biochemical data to identify how specific neurotransmitter receptor combinations produce distinct emotional and cognitive states. Using these predictions, the company designs novel psychoactive compounds intended to induce precise therapeutic mental states — without the hallucinations associated with traditional psychedelic therapies — for psychiatric indications with high unmet medical need.

The company's lead asset is MSD-001, a proprietary oral formulation of 5-MeO-MiPT (a 5-HT2A agonist and neuroplastogen) intended to serve as a neutral psychoactive base for fixed-dose combinations targeting specific states such as empathy, awe, and enhanced aesthetic perception. MSD-001 completed a first-in-human Phase I study in September 2025, demonstrating safety, tolerability, dose-proportional linear pharmacokinetics, and the first clinical validation of the Osmanthus platform's design predictions. Additional programs include MSD-X02 (a novel CNS target series) and MSD-XXX (future high-throughput screening programs). The FDA approved an AI-designed clinical trial of MSD-001 in September 2024.

Mindstate operates as a pre-revenue clinical-stage biotech. It has no commercial products and no disclosed pricing; revenue is expected to flow from prescription drug sales through traditional pharmaceutical distribution channels upon FDA approval. Capital to date totals approximately $24.3 million across a $11.5 million seed round (February 2022, led by Initialized Capital with Y Combinator, Metaplanet, Day One Ventures, and high-profile angels including founders of OpenAI, Neuralink, Instacart, Coinbase, and Twitch), an additional ~$12.7 million round (November 2024), Y Combinator's standard investment, and smaller accelerator tranches. The team of approximately 16 includes executives with prior FDA approvals for CNS products such as LATUDA and FINTEMPLA.

Short descriptiontext

Mindstate Design Labs is a clinical-stage AI neuroengineering platform that designs novel psychoactive therapeutics for psychiatric indications, using its Osmanthus platform to map neurotransmitter interactions underlying specific mental states. Its lead asset, MSD-001, completed Phase I trials in September 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, psychedelic therapeutics, neuroengineering platform, psychiatric pharmaceuticals, psychoactive compound design
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Psychiatric Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Sales
TypeOne Time License
Description

Once regulatory approval is obtained, the company plans to commercialize its proprietary drug compounds through traditional pharmaceutical distribution channels. Revenue will come from prescription drug sales for psychiatric indications.

mindstate.design
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mindstate Design Labs is a clinical-stage AI neuroengineering platform and drug development company. Its Osmanthus platform uses AI/ML to map the biological basis of emotion, perception, and cognition by synthesizing 60,000 human reports of psychoactive drug effects with biochemical data. The company develops proprietary pharmaceutical compounds — led by MSD-001, a 5-MeO-MiPT-based neuroplastogen — designed as neutral psychoactive bases for fixed-dose combinations targeting psychiatric indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I trial confirmed MSD-001 was safe and well-tolerated across dose ranges with no hallucinations and no serious adverse events
+2 more records
Product overview1 text field

Mindstate Design Labs is a clinical-stage AI neuroengineering platform company operating as a platform-plus-pipeline architecture. The core Osmanthus platform maps molecular biology underlying emotion, perception, and cognition to identify neurotransmitter interactions producing distinct mental states. The platform supports multiple drug programs: MSD-001 (lead asset, proprietary oral formulation of 5-MeO-MiPT) serves as a neutral psychoactive base for fixed-dose combinations targeting psychiatric conditions; MSD-X02 acts on novel CNS targets; and MSD-XXX future programs use high-throughput screening for broader psychoactive effect optimization. The company progressed MSD-001 into human studies to demonstrate precision-designed therapeutic states.

Product and service5 records
1Osmanthus Platform
CategoryAI Drug Discovery Platform
Description

AI-powered neuroengineering platform that maps how specific neurotransmitter receptor combinations produce distinct emotional and cognitive states, supporting internal drug discovery and pipeline development for psychiatric indications.

2MSD-001 (Lead Asset)
CategoryPharmaceutical Compound (CNS / Psychiatric)
Description

Proprietary oral pharmaceutical formulation of 5-MeO-MiPT (a 5-HT2A agonist and neuroplastogen) designed as a neutral psychoactive base to temporarily enable significant emotional and cognitive flexibility, under clinical evaluation for psychiatric indications.

3MSD-X02 Program Series
CategoryPharmaceutical Pipeline Program
Description

Pipeline program series targeting a novel CNS target to produce select psychoactive effects, intended for therapeutic applications in psychiatry.

4MSD-XXX Future Programs
CategoryPharmaceutical Pipeline Program
Description

Pipeline of future development programs derived from high-throughput Osmanthus screening, optimizing single-molecule, multi-target candidates for broader psychoactive effect profiles.

5MSD-001 Fixed-Dose Combination Programs
CategoryPharmaceutical Combination Product
Description

Fixed-dose combination pharmaceutical products using MSD-001 as a neutral psychoactive base, each designed to reliably induce a specific therapeutic state (e.g., empathy, awe, enhanced aesthetic perception) for psychiatric indications.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Mind Medicine (MindMed)
TypeDirect peer
Description

Public clinical-stage biotech developing psychedelic-inspired therapeutics for psychiatric conditions. Directly comparable in target indication space (anxiety, depression) and use of tryptamine-class molecules; Mindstate's CSO previously led global development at MindMed.

TypeDirect peer
Description

Public clinical-stage company developing psilocybin-based therapies for treatment-resistant depression. Competes in the same psychedelic-psychiatry category with substantially more capital and Phase IIb/III data already generated; a key benchmark for Mindstate's regulatory and commercial trajectory.

3atai Life Sciences
TypeDirect peer
Description

Public clinical-stage biotech with a platform of psychedelic and non-psychedelic mental health therapies. Comparable in psychiatric indication focus and platform-plus-pipeline model, with significantly greater funding and a broader pipeline.

TypeDirect peer
Description

Clinical-stage psychedelic therapeutics company developing deuterated tryptamine analogs for depression and other psychiatric indications. Comparable mechanism space (5-HT2A agonists) and similar strategy of designing novel chemical entities inspired by psychedelics.

TypeDirect peer
Description

Clinical-stage biotech developing mebufotenin (5-MeO-DMT) for treatment-resistant depression. Directly comparable in 5-MeO-tryptamine mechanism and depression indication; serves as a near-mechanistic reference for MSD-001's regulatory and clinical readouts.

TypeDirect peer
Description

Clinical-stage psychedelic medicine company developing short-duration psychedelic compounds for neuropsychiatric conditions. Comparable in pursuing intermittent-dosing psychedelic-inspired therapeutics with patient-access-friendly pharmacokinetics.

TypeDirect peer
Description

Clinical-stage biotech developing DMT-based therapies for major depressive disorder. Comparable target indication and psychedelic-inspired approach; useful peer for evaluating clinical-trial design and regulatory engagement strategies.

TypeBroad incumbent
Description

Public AI-driven drug discovery company with a platform-plus-pipeline model across multiple therapeutic areas. Comparable in using AI/ML to systematically generate drug candidates, but operates at much greater scale and broader therapeutic scope than Mindstate's psychiatric focus.

TypeBroad incumbent
Description

Public computational drug discovery company combining physics-based modeling with ML. Comparable in using advanced computational chemistry to design novel compounds, though Schrödinger's platform is more general-purpose and serves external clients plus internal pipeline.

TypeBroad incumbent
Description

Clinical-stage AI-native drug discovery company applying ML to generative biology and chemistry. Comparable in platform-plus-pipeline AI-drug-discovery model, though Insitro has progressed to multiple clinical candidates with substantially greater funding.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mindstate Design Labs

Psychiatric Pharmaceuticalsmindstate.design

Mindstate Design Labs is a clinical-stage AI neuroengineering platform that designs novel psychoactive therapeutics for psychiatric indications, using its Osmanthus platform to map neurotransmitter interactions underlying specific mental states. Its lead asset, MSD-001, completed Phase I trials in September 2025.

What Mindstate Design Labs does

Mindstate Design Labs is a clinical-stage AI neuroengineering platform and drug development company founded in 2021 and headquartered in South San Francisco. The company's core technology, the Osmanthus platform, applies multi-agent large language models, custom embedding models, Bayesian neural networks, and biomedical knowledge graph analysis to a proprietary dataset of more than 60,000 human reports of psychoactive drug effects, synthesizing subjective phenomenology with biochemical data to identify how specific neurotransmitter receptor combinations produce distinct emotional and cognitive states. Using these predictions, the company designs novel psychoactive compounds intended to induce precise therapeutic mental states — without the hallucinations associated with traditional psychedelic therapies — for psychiatric indications with high unmet medical need.

The company's lead asset is MSD-001, a proprietary oral formulation of 5-MeO-MiPT (a 5-HT2A agonist and neuroplastogen) intended to serve as a neutral psychoactive base for fixed-dose combinations targeting specific states such as empathy, awe, and enhanced aesthetic perception. MSD-001 completed a first-in-human Phase I study in September 2025, demonstrating safety, tolerability, dose-proportional linear pharmacokinetics, and the first clinical validation of the Osmanthus platform's design predictions. Additional programs include MSD-X02 (a novel CNS target series) and MSD-XXX (future high-throughput screening programs). The FDA approved an AI-designed clinical trial of MSD-001 in September 2024.

Mindstate operates as a pre-revenue clinical-stage biotech. It has no commercial products and no disclosed pricing; revenue is expected to flow from prescription drug sales through traditional pharmaceutical distribution channels upon FDA approval. Capital to date totals approximately $24.3 million across a $11.5 million seed round (February 2022, led by Initialized Capital with Y Combinator, Metaplanet, Day One Ventures, and high-profile angels including founders of OpenAI, Neuralink, Instacart, Coinbase, and Twitch), an additional ~$12.7 million round (November 2024), Y Combinator's standard investment, and smaller accelerator tranches. The team of approximately 16 includes executives with prior FDA approvals for CNS products such as LATUDA and FINTEMPLA.

Mindstate Design Labs firmographics

Firmographics
Name
Mindstate Design Labs
Legal name
Mindstate Design Labs Inc.
Website
https://mindstate.design
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Mindstate Design Labs is a clinical-stage AI neuroengineering platform that designs novel psychoactive therapeutics for psychiatric indications, using its Osmanthus platform to map neurotransmitter interactions underlying specific mental states. Its lead asset, MSD-001, completed Phase I trials in September 2025.
Ownership category
akta.pro rank

Mindstate Design Labs industry classification

Industry
Product category
Psychiatric Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Psychedelic therapeutics
  • Neuroengineering platform
  • Psychiatric pharmaceuticals
  • Psychoactive compound design

Where Mindstate Design Labs is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mindstate Design Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Drug Sales: Once regulatory approval is obtained, the company plans to commercialize its proprietary drug compounds through traditional pharmaceutical distribution channels. Revenue will come from prescription drug sales for psychiatric indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Mindstate Design Labs product offering

Product offering

Core offering

Mindstate Design Labs is a clinical-stage AI neuroengineering platform and drug development company. Its Osmanthus platform uses AI/ML to map the biological basis of emotion, perception, and cognition by synthesizing 60,000 human reports of psychoactive drug effects with biochemical data. The company develops proprietary pharmaceutical compounds — led by MSD-001, a 5-MeO-MiPT-based neuroplastogen — designed as neutral psychoactive bases for fixed-dose combinations targeting psychiatric indications.

Product overview

Mindstate Design Labs is a clinical-stage AI neuroengineering platform company operating as a platform-plus-pipeline architecture. The core Osmanthus platform maps molecular biology underlying emotion, perception, and cognition to identify neurotransmitter interactions producing distinct mental states. The platform supports multiple drug programs: MSD-001 (lead asset, proprietary oral formulation of 5-MeO-MiPT) serves as a neutral psychoactive base for fixed-dose combinations targeting psychiatric conditions; MSD-X02 acts on novel CNS targets; and MSD-XXX future programs use high-throughput screening for broader psychoactive effect optimization. The company progressed MSD-001 into human studies to demonstrate precision-designed therapeutic states.

Differentiator

Problem solved

Functional benefit

Products and services

  • Osmanthus Platform AI-powered neuroengineering platform that maps how specific neurotransmitter receptor combinations produce distinct emotional and cognitive states, supporting internal drug discovery and pipeline development for psychiatric indications.
  • MSD-001 (Lead Asset) Proprietary oral pharmaceutical formulation of 5-MeO-MiPT (a 5-HT2A agonist and neuroplastogen) designed as a neutral psychoactive base to temporarily enable significant emotional and cognitive flexibility, under clinical evaluation for psychiatric indications.
  • MSD-X02 Program Series Pipeline program series targeting a novel CNS target to produce select psychoactive effects, intended for therapeutic applications in psychiatry.
  • MSD-XXX Future Programs Pipeline of future development programs derived from high-throughput Osmanthus screening, optimizing single-molecule, multi-target candidates for broader psychoactive effect profiles.
  • MSD-001 Fixed-Dose Combination Programs Fixed-dose combination pharmaceutical products using MSD-001 as a neutral psychoactive base, each designed to reliably induce a specific therapeutic state (e.g., empathy, awe, enhanced aesthetic perception) for psychiatric indications.

Quantifiable outcome

  • Phase I trial confirmed MSD-001 was safe and well-tolerated across dose ranges with no hallucinations and no serious adverse events
  • +2 more outcomes

Companies that use Mindstate Design Labs

Customer profile

Segments1 record

Ideal customer profiles1 record

Mindstate Design Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature3 records

Mindstate Design Labs partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Mindstate Design Labs competitors and assessment

Company assessment

Direct peers

  • Mind Medicine (MindMed): Public clinical-stage biotech developing psychedelic-inspired therapeutics for psychiatric conditions. Directly comparable in target indication space (anxiety, depression) and use of tryptamine-class molecules; Mindstate's CSO previously led global development at MindMed.
  • Compass Pathways: Public clinical-stage company developing psilocybin-based therapies for treatment-resistant depression. Competes in the same psychedelic-psychiatry category with substantially more capital and Phase IIb/III data already generated; a key benchmark for Mindstate's regulatory and commercial trajectory.
  • atai Life Sciences: Public clinical-stage biotech with a platform of psychedelic and non-psychedelic mental health therapies. Comparable in psychiatric indication focus and platform-plus-pipeline model, with significantly greater funding and a broader pipeline.
  • Cybin: Clinical-stage psychedelic therapeutics company developing deuterated tryptamine analogs for depression and other psychiatric indications. Comparable mechanism space (5-HT2A agonists) and similar strategy of designing novel chemical entities inspired by psychedelics.
  • GH Research: Clinical-stage biotech developing mebufotenin (5-MeO-DMT) for treatment-resistant depression. Directly comparable in 5-MeO-tryptamine mechanism and depression indication; serves as a near-mechanistic reference for MSD-001's regulatory and clinical readouts.
  • Beckley Psytech: Clinical-stage psychedelic medicine company developing short-duration psychedelic compounds for neuropsychiatric conditions. Comparable in pursuing intermittent-dosing psychedelic-inspired therapeutics with patient-access-friendly pharmacokinetics.
  • Small Pharma: Clinical-stage biotech developing DMT-based therapies for major depressive disorder. Comparable target indication and psychedelic-inspired approach; useful peer for evaluating clinical-trial design and regulatory engagement strategies.

Broad incumbents

  • Recursion Pharmaceuticals: Public AI-driven drug discovery company with a platform-plus-pipeline model across multiple therapeutic areas. Comparable in using AI/ML to systematically generate drug candidates, but operates at much greater scale and broader therapeutic scope than Mindstate's psychiatric focus.
  • Schrödinger: Public computational drug discovery company combining physics-based modeling with ML. Comparable in using advanced computational chemistry to design novel compounds, though Schrödinger's platform is more general-purpose and serves external clients plus internal pipeline.
  • Insitro: Clinical-stage AI-native drug discovery company applying ML to generative biology and chemistry. Comparable in platform-plus-pipeline AI-drug-discovery model, though Insitro has progressed to multiple clinical candidates with substantially greater funding.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Mindstate Design Labs social profiles

Digital presence

Mindstate Design Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mindstate Design Labs leadership team

Management profile

Number of profiles

Profiles15 records

Mindstate Design Labs funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mindstate Design Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mindstate Design Labs

What does Mindstate Design Labs do?

Mindstate Design Labs is a clinical-stage AI neuroengineering platform and drug development company. Its Osmanthus platform uses AI/ML to map the biological basis of emotion, perception, and cognition by synthesizing 60,000 human reports of psychoactive drug effects with biochemical data. The company develops proprietary pharmaceutical compounds — led by MSD-001, a 5-MeO-MiPT-based neuroplastogen — designed as neutral psychoactive bases for fixed-dose combinations targeting psychiatric indications.

Is Mindstate Design Labs a public or private company?

Mindstate Design Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mindstate Design Labs founded?

Mindstate Design Labs was founded in 2021. It employs 11 to 50 people.

Where is Mindstate Design Labs based?

Mindstate Design Labs is headquartered in San Francisco, United States, in the North America region.

How does Mindstate Design Labs make money?

One revenue line is on record: pharmaceutical Drug Sales.

Who are Mindstate Design Labs's main competitors?

Direct peers on record are Mind Medicine (MindMed), Compass Pathways, atai Life Sciences, Cybin, GH Research, Beckley Psytech and Small Pharma. Broad incumbents are Recursion Pharmaceuticals, Schrödinger and Insitro.

Does Mindstate Design Labs have an API?

No public API is recorded for Mindstate Design Labs.

What industry is Mindstate Design Labs in?

Mindstate Design Labs's product category is Psychiatric Pharmaceuticals. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LinkedInMindstate Design LabsMindstate Design Labs completed its first human trial of its neurotech platform for designing mental states. The Phase I study of MSD-001, an oral 5-HT2A agonist, was safe and well-tolerated, with no serious adverse events. The company plans to use MSD-001 in fixed-dose combinations to elicit specific psychoactive effects without hallucinations.YahooStartups Are Biohacking Psychedelic Drugs to Make Sure You Never Have a Bad Trip AgainStartups are developing safer psychedelic drugs for therapy, including R-MDMA and Moxy. MindMed's R-MDMA shows fewer side effects, and Mindstate's Moxy targets specific serotonin receptors. Human trials are ongoing, with approval for Moxy trials granted.Benzinga'Tofu-Like' Psychedelic Gets FDA Nod - Mindstate's AI-Designed Therapy To Begin Human TrialsMindstate Design Labs received FDA and EMA approval to begin human trials for its compound MSD-001, a serotonin-specific psychedelic. The Phase 1 trial at Leiden's Centre for Human Drug Research will involve 52 healthy participants. The company aims to use the drug to design targeted altered states of consciousness for novel therapies.GenengnewsTransforming Psychedelics into Approved MedicinesMultiple companies are developing psychedelic medicines for mental health, including Psilera, Delix, Mindset, Compass Pathways, and Seelos. Compass Pathways reported a Phase IIb trial of its psilocybin formulation COMP360 in treatment-resistant depression showed significant symptom reduction. The companies aim to advance these therapies through clinical trials and partnerships.BloombergAre Hallucinogen Look-Alikes Illegal? DEA Delay Creates LimboThe DEA withdrew its bid to schedule five hallucinogenic compounds as Schedule 1 drugs, sending them back to HHS for review. The move delays the decision, leaving companies like Tactogen and Mindstate Labs in regulatory limbo. The outcome could affect research funding and public health risks from designer drugs.WsjInvestors See Far Out Profits in Psychedelic MedicineEmpath Ventures, a psychedelic medicine VC firm, raised $2.1 million of a $10 million target for its first fund. The firm is backing companies like Mindstate Design Labs and Wavepaths, with investors betting on FDA approval of MDMA-assisted therapy in 2023.TechnicalMindstate Design Labs raised an $11.5M seed round for psychedelic-inspired therapeuticsPittsburgh-based biotech Mindstate Design Labs raised an $11.5 million seed round to advance psychedelic-inspired therapeutics, including an MDMA-based PTSD treatment. The funding, led by Initialized Capital, will support team growth and clinical trials, with the company aiming to launch trials by mid-2023.VICEThe Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard OfCompanies are developing novel psychedelic compounds to improve on classic drugs, aiming for shorter trips, fewer side effects, or non-hallucinogenic neuroplasticity. The DEA has scheduled five new tryptamine hallucinogens, adding regulatory hurdles. The future of psychedelic medicine will include both known and second- and third-generation compounds.